EXEL Cash-Secured Put Strategy
EXEL (Exelixis, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F.
EXEL (Exelixis, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $13.77B, a trailing P/E of 16.98, a beta of 0.44 versus the broader market, a 52-week range of 33.76-55.15, average daily share volume of 2.7M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how EXEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.44 indicates EXEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a cash-secured put on EXEL?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current EXEL snapshot
As of June 30, 2026, spot at $54.48, ATM IV 39.80%, IV rank 45.55%, expected move 11.41%. The cash-secured put on EXEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 52-day expiry.
Why this cash-secured put structure on EXEL specifically: EXEL IV at 39.80% is mid-range versus its 1-year history, so the credit collected on a EXEL cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 11.41% (roughly $6.22 on the underlying). The 52-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EXEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on EXEL should anchor to the underlying notional of $54.48 per share and to the trader's directional view on EXEL stock.
EXEL cash-secured put setup
The EXEL cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EXEL near $54.48, the first option leg uses a $50.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EXEL chain at a 52-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EXEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $50.00 | $1.68 |
EXEL cash-secured put risk and reward
- Net Premium / Debit
- +$167.50
- Max Profit (per contract)
- $167.50
- Max Loss (per contract)
- -$4,831.50
- Breakeven(s)
- $48.33
- Risk / Reward Ratio
- 0.035
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
EXEL cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on EXEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$4,831.50 |
| $12.05 | -77.9% | -$3,627.03 |
| $24.10 | -55.8% | -$2,422.56 |
| $36.14 | -33.7% | -$1,218.08 |
| $48.19 | -11.5% | -$13.61 |
| $60.23 | +10.6% | +$167.50 |
| $72.28 | +32.7% | +$167.50 |
| $84.32 | +54.8% | +$167.50 |
| $96.37 | +76.9% | +$167.50 |
| $108.41 | +99.0% | +$167.50 |
When traders use cash-secured put on EXEL
Cash-secured puts on EXEL earn premium while a trader waits to acquire EXEL stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning EXEL.
EXEL thesis for this cash-secured put
The market-implied 1-standard-deviation range for EXEL extends from approximately $48.26 on the downside to $60.70 on the upside. A EXEL cash-secured put lets a trader earn premium while waiting to acquire EXEL at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current EXEL IV rank near 45.55% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on EXEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EXEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EXEL-specific events.
EXEL cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EXEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EXEL alongside the broader basket even when EXEL-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on EXEL carry tail risk when realized volatility exceeds the implied move; review historical EXEL earnings reactions and macro stress periods before sizing. Always rebuild the position from current EXEL chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on EXEL?
- A cash-secured put on EXEL is the cash-secured put strategy applied to EXEL (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With EXEL stock trading near $54.48, the strikes shown on this page are snapped to the nearest listed EXEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EXEL cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the EXEL cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 39.80%), the computed maximum profit is $167.50 per contract and the computed maximum loss is -$4,831.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EXEL cash-secured put?
- The breakeven for the EXEL cash-secured put priced on this page is roughly $48.33 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 11.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on EXEL?
- Cash-secured puts on EXEL earn premium while a trader waits to acquire EXEL stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning EXEL.
- How does current EXEL implied volatility affect this cash-secured put?
- EXEL ATM IV is at 39.80% with IV rank near 45.55%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.